Official Title
The Role of Gut Microbiota in Hypertension: Brain-Gut Microbiome-Immune Axis in Hypertension
Brief Title
The Role of Gut Microbiota in Hypertension
Protocol ID
NCT02188381
Lead Sponsor
University of Florida
Brief Summary
Hypertension is the single most prevalent risk factor for heart diseases, heart failure,
kidney failure and stroke. About 1 in 3 adults in the United States have hypertension.
Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH).
Inflammation has been implicated in the pathogenesis of the hypertension. Additional data
suggests the involvement of gut microbiota in host normal cardiovascular functions and
pathophysiology. Accumulating evidence demonstrates that antibiotic treatment benefits
patients with acute coronary syndromes and reduces the incidence of ischemic
cardiovascular events. Even though these studies did not address effects of antibiotic
treatment on the gut microbiota, it is possible that gut microbiota could affect
neurologic inflammation. Finally, intestinal microbiota has recently been proposed to
modulate blood pressure (BP) through production of short-chain fatty acids. In order to
investigate this, the investigators hypothesize that gut microbiota is involved in the
neuroinflammation-mediated initiation and establishment of RH, and targeting gut
microbiota by minocycline would produce beneficial outcomes in RH.
Detailed Description
This is a prospective cohort design. This study will enroll 388 subjects: 81 patients
without HTN as a reference group, 81 patients with controlled HTN, 55 patients with
uncontrolled HTN, 55 with remodeled RH, and 81 patients with RH to characterize gut
microbiota composition. Subjects will provide stool samples for analysis. Subjects will
also provide a blood sample for inflammatory marker and stem cell analysis.
Enrollment Count
292 participants
Eligibility Criteria
Inclusion Criteria:
- age >18 and <80
- is competent and willing to provide consent
Inclusion criteria for each subject group:
- Control subjects will have a systolic BP <140mmHg with no cardiovascular disease
- Patients with controlled hypertension
- Patients with uncontrolled hypertension
- Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg
despite ≥3 anti-hypertensive medications of different classes one of which should be
a diuretic
- Patients who are no longer RH subjects and have normal blood pressure
- Subjects participating in NCT 02133872 will be eligible to participate
Exclusion Criteria:
- currently pregnant or have been pregnant in the last 6 months;
- antibiotic treatment within 2 months of study enrollment;
- currently taking a medication (e.g., antibiotic, anti-inflammatory agents,
glucocorticoids or other immune modulating medications);
- unwilling to discontinue vitamin or supplements, including probiotics, potentially
affecting gut microbiota (vitamins/supplements and medications that possibly affect
the gut microbiota should be discontinued for at least 2wks prior to stool
collection);
- history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose
intolerance, chronic pancreatitis or other malabsorption disorder.
Filters
Hypertension
COMPLETED
ADULT
OLDER_ADULT